Kolon Life Science Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 109.54 million compared to KRW 119.89 million a year ago. Net income was KRW 2,133.31 million compared to net loss of KRW 1,374.92 million a year ago.

Basic earnings per share from continuing operations was KRW 187 compared to basic loss per share from continuing operations of KRW 121 a year ago. Diluted earnings per share from continuing operations was KRW 169 compared to diluted loss per share from continuing operations of KRW 121 a year ago. Basic earnings per share was KRW 187 compared to basic loss per share of KRW 121 a year ago.

Diluted earnings per share was KRW 169.